HEPATITIS C LEUKOPAK
Hepatitis C (HCV) primarily causes a long-lasting liver disease. It is spread by contact with infected blood. It first became evident in 1974 that a non A/non B hepatitis virus existed. Finally, a test was discovered that could be used to identify the virus in 1989 and from the early 1990s all blood units were screened for HCV. Hepatitis C is more likely than Hepatitis B to cause liver disease.
Leukopaks are obtained by a donation process where blood is withdrawn from the donor via leukapheresis utilizing an aphresis machine such as the Spectra Optia. The donor’s white blood cells are selectively collected and the remaining blood is reinfused to the body.
PPA's fresh Hepatitis C leukopaks are obtained by aphresis from donors with Hepatitis C. All of our donors are fully consented and IRB approved.
Products sold or distributed by Physicians Plasma Alliance or PPA Research Group are intended and labeled for "Research Use Only" and are never to be used in humans, human trials or used in a manner inconsistent with "Research Use Only" labeling.